Limits...
A survey on the distribution of healthy people with different anti-tumour ability.

Gao Y, Xu X, Dong Z, Jiang C, Gao J, Hu J, Gui J, Wang H, Tian Y - Arch Med Sci (2010)

Bottom Line: The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells.We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells.From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, China.

ABSTRACT

Introduction: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability.

Material and methods: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios. The survival rate for target cells was observed and counted by Fluoroskan. Immune function for 200 healthy people was analysed by flow cytometry.

Results: The results obtained by confocal microscopy revealed that human blood leukocytes possessed direct anti-tumour activity. The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells. We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7 cells is stronger than the leukocyte capacity for killing A549 cells and Hela cells. We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells. The number of healthy people with the strongest anti-tumour ability was highest when the target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela cells was correlated with T, B and NK lymphocytes.

Conclusions: From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

No MeSH data available.


Related in: MedlinePlus

The survival rate for target cells was counted by Fluoroskan at different ratios for effector cells and target cells. The results indicated that the survival rate for tumour cells was different for different effector cells with the same ratio (**P < 0.01). In the condition of a 20 : 1 ratio of effector cells to target cells, the survival rate for tumour cells was the lowest. The survival rate for A549 was 0.64 ±0.12. The survival rate for MCF-7 cells was 0.38 ±0.17. This showed that the MCF-7 cell killing capacity of leukocytes is stronger than the killing capacity for A549 cells. Leukocytes from healthy people act differently in their effect on different tumour cells
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3298353&req=5

Figure 5: The survival rate for target cells was counted by Fluoroskan at different ratios for effector cells and target cells. The results indicated that the survival rate for tumour cells was different for different effector cells with the same ratio (**P < 0.01). In the condition of a 20 : 1 ratio of effector cells to target cells, the survival rate for tumour cells was the lowest. The survival rate for A549 was 0.64 ±0.12. The survival rate for MCF-7 cells was 0.38 ±0.17. This showed that the MCF-7 cell killing capacity of leukocytes is stronger than the killing capacity for A549 cells. Leukocytes from healthy people act differently in their effect on different tumour cells

Mentions: The results showed that the survival rate for target cells was the lowest in the condition of a 20 : 1 ratio of effector cells to target cells. The survival rate for A549 was 0.64 ±0.12. The survival rate for MCF-7 cell was 0.38 ±0.17 (Figure 5). From the above, we can speculate that in 200 healthy people the capacity of leukocytes for killing MCF-7 cells is stronger than the capacity of leukocytes for killing A549 cells. This is consistent with the results of Fig. 2-4. Furthermore, leukocytes of healthy people act differently in their effect on different tumour cells.


A survey on the distribution of healthy people with different anti-tumour ability.

Gao Y, Xu X, Dong Z, Jiang C, Gao J, Hu J, Gui J, Wang H, Tian Y - Arch Med Sci (2010)

The survival rate for target cells was counted by Fluoroskan at different ratios for effector cells and target cells. The results indicated that the survival rate for tumour cells was different for different effector cells with the same ratio (**P < 0.01). In the condition of a 20 : 1 ratio of effector cells to target cells, the survival rate for tumour cells was the lowest. The survival rate for A549 was 0.64 ±0.12. The survival rate for MCF-7 cells was 0.38 ±0.17. This showed that the MCF-7 cell killing capacity of leukocytes is stronger than the killing capacity for A549 cells. Leukocytes from healthy people act differently in their effect on different tumour cells
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3298353&req=5

Figure 5: The survival rate for target cells was counted by Fluoroskan at different ratios for effector cells and target cells. The results indicated that the survival rate for tumour cells was different for different effector cells with the same ratio (**P < 0.01). In the condition of a 20 : 1 ratio of effector cells to target cells, the survival rate for tumour cells was the lowest. The survival rate for A549 was 0.64 ±0.12. The survival rate for MCF-7 cells was 0.38 ±0.17. This showed that the MCF-7 cell killing capacity of leukocytes is stronger than the killing capacity for A549 cells. Leukocytes from healthy people act differently in their effect on different tumour cells
Mentions: The results showed that the survival rate for target cells was the lowest in the condition of a 20 : 1 ratio of effector cells to target cells. The survival rate for A549 was 0.64 ±0.12. The survival rate for MCF-7 cell was 0.38 ±0.17 (Figure 5). From the above, we can speculate that in 200 healthy people the capacity of leukocytes for killing MCF-7 cells is stronger than the capacity of leukocytes for killing A549 cells. This is consistent with the results of Fig. 2-4. Furthermore, leukocytes of healthy people act differently in their effect on different tumour cells.

Bottom Line: The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells.We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells.From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Chinese PLA General Hospital, China.

ABSTRACT

Introduction: The aim of the study was to explore the distribution of healthy people with different anti-tumour ability.

Material and methods: Leukocytes were separated by the Ficoll-Hypaque density gradient centrifugal method. Then they were mixed with A549, MCF-7 and Hela cells at different ratios. The survival rate for target cells was observed and counted by Fluoroskan. Immune function for 200 healthy people was analysed by flow cytometry.

Results: The results obtained by confocal microscopy revealed that human blood leukocytes possessed direct anti-tumour activity. The survival rate for tumour cells was the lowest in the condition of 20:1 ratio of effector cells to target cells. We speculated that in 200 healthy people the leukocyte capacity for killing MCF-7 cells is stronger than the leukocyte capacity for killing A549 cells and Hela cells. We also found that the distribution for 200 healthy people with different anti-tumour ability was different for different tumour cells. The number of healthy people with the strongest anti-tumour ability was highest when the target cells were MCF-7 cells. Moreover, the survival of A549, MCF-7 and Hela cells was correlated with T, B and NK lymphocytes.

Conclusions: From the above, we can select healthy individuals with strong anti-tumour ability as anti-tumour donors according to their distribution with different anti-tumour ability, which opened up a new direction for fighting human cancer.

No MeSH data available.


Related in: MedlinePlus